Depo-Provera Lawsuit Lawyer – Georgia

Millions of women in the United States have used Depo-Provera (medroxyprogesterone acetate), an injectable hormonal contraceptive manufactured by Pfizer Inc. (originally developed and marketed by Upjohn, later Pharmacia). Administered as an intramuscular injection every three months, Depo-Provera has been one of the most widely prescribed birth control methods since its FDA approval in 1992. What many women were never adequately warned about is the growing body of scientific evidence linking prolonged Depo-Provera use to an increased risk of developing meningiomas — tumors that develop in the membranes (meninges) surrounding the brain and spinal cord.

A major 2024 study published in the British Medical Journal (BMJ) confirmed what researchers had suspected for years: prolonged use of injectable progestogen contraceptives, including Depo-Provera, is associated with a significantly elevated risk of intracranial meningioma. This study, along with growing evidence from France and other countries where similar progestogen-based drugs have already been restricted, has sparked a wave of lawsuits against Pfizer.

At Wetherington Law Firm, our Georgia mass tort attorneys are representing women who developed meningiomas after using Depo-Provera. We are committed to holding Pfizer accountable for failing to adequately warn patients and healthcare providers about this serious risk.

What Is Depo-Provera?

Depo-Provera is the brand name for depot medroxyprogesterone acetate (DMPA), a synthetic progestogen that works by suppressing ovulation, thinning the uterine lining, and thickening cervical mucus to prevent pregnancy. It is administered as an intramuscular injection (typically in the upper arm or buttock) once every 12 to 13 weeks.

How Depo-Provera Works

Medroxyprogesterone acetate is a synthetic form of progesterone, one of the primary female sex hormones. When injected, DMPA creates a sustained high level of synthetic progestogen in the body that:

• Prevents the pituitary gland from releasing hormones that trigger ovulation
• Alters the uterine lining to make implantation unlikely
• Changes cervical mucus consistency to impede sperm transport

Because it is injected and slowly absorbed from the injection site, DMPA maintains relatively high and continuous progestogen levels in the bloodstream for the entire 12-week injection interval. This continuous exposure to synthetic progestogen is central to the mechanism by which Depo-Provera may promote meningioma growth.

Prevalence of Use

Depo-Provera has been widely prescribed in the United States and worldwide since its FDA approval in October 1992. According to CDC data, approximately 2 million women in the U.S. use injectable contraceptives annually. Globally, DMPA is one of the most widely used contraceptive methods, particularly in developing countries where its ease of administration (no daily pills, no need for refrigeration) makes it a practical option.

In Georgia, Depo-Provera has been prescribed through OB-GYN offices, family planning clinics, federally qualified health centers, college health services, and public health departments. Many Georgia women have used Depo-Provera for years or even decades, accumulating significant cumulative exposure to synthetic progestogen.

The Connection Between Depo-Provera and Meningiomas

What Are Meningiomas?

Meningiomas are tumors that arise from the meninges — the three layers of protective membranes that surround the brain and spinal cord. They are the most common type of primary brain tumor, accounting for approximately 40% of all primary brain tumors diagnosed in the United States.

Meningiomas are classified by the World Health Organization (WHO) into three grades:

• Grade 1 (benign): The most common type, accounting for approximately 80% of meningiomas. While technically benign (non-cancerous), these tumors can still cause serious symptoms depending on their size and location, including severe headaches, vision changes, seizures, cognitive impairment, and neurological deficits.
• Grade 2 (atypical): These tumors are more aggressive and more likely to recur after treatment. They account for approximately 15-18% of meningiomas.
• Grade 3 (anaplastic/malignant): Rare but aggressive cancerous tumors that account for approximately 2-3% of meningiomas.

Even “benign” meningiomas can be life-altering. Depending on their location, they can compress vital brain structures, causing seizures, paralysis, vision loss, hearing loss, personality changes, and cognitive decline. Treatment often requires brain surgery (craniotomy) and/or radiation therapy, both of which carry significant risks.

The Progesterone Receptor Connection

The link between progestogen exposure and meningioma development is biologically well-established. Meningiomas are unique among brain tumors in that they frequently express progesterone receptors (PR). Studies have found that approximately 60-80% of meningiomas are progesterone-receptor positive, meaning they have receptors on their surface that bind to progesterone and progesterone-like compounds.

When synthetic progestogens like medroxyprogesterone acetate bind to these receptors, they can:

• Stimulate meningioma cell growth and proliferation
• Inhibit apoptosis (programmed cell death) in meningioma cells
• Promote angiogenesis (new blood vessel formation) that feeds tumor growth
• Upregulate growth factors including vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)

This explains why meningiomas are approximately twice as common in women as in men and why they tend to grow during pregnancy (when progesterone levels are naturally elevated). The sustained, artificially elevated progestogen levels caused by Depo-Provera injections essentially provide continuous growth stimulation to progesterone-receptor-positive meningioma cells.

Key Scientific Evidence

Multiple studies have established the connection between progestogen use and meningioma risk:

• BMJ Study (2024): A large population-based study published in the British Medical Journal found that prolonged use of injectable medroxyprogesterone acetate (Depo-Provera) was associated with an elevated risk of intracranial meningioma. The risk increased with duration of use, with the highest risk observed in women who used injectable progestogen contraceptives for three or more years.
• French CNAM Study (Nguyen et al., 2021): A study using French national health insurance data analyzed the association between progestogen use and meningioma. The study found that prolonged use of certain high-dose progestogens, including cyproterone acetate, chlormadinone acetate, and nomegestrol acetate, was associated with significantly increased meningioma risk. This study led French health authorities to restrict the use of several progestogen products.
• WHO IARC Assessment: The International Agency for Research on Cancer has classified combined estrogen-progestogen contraceptives as Group 1 carcinogens, though the meningioma risk is a separate and distinct concern from the cancer risks traditionally associated with hormonal contraceptives.
• Wigertz et al. (2006): A case-control study published in the International Journal of Cancer found that long-term use of hormonal contraceptives was associated with increased meningioma risk, with the risk increasing with duration of use.
• Hormonal contraceptive meta-analyses: Multiple meta-analyses have found consistent associations between exogenous progestogen exposure and meningioma risk across different populations and study designs.

Current Status of Depo-Provera Litigation

Depo-Provera meningioma lawsuits represent an emerging area of mass tort litigation that has been building rapidly:

Federal Litigation

As of early 2025, a growing number of lawsuits have been filed against Pfizer Inc. in federal courts across the country. Plaintiffs allege that Pfizer knew or should have known about the meningioma risk associated with prolonged Depo-Provera use and failed to adequately warn patients and prescribing physicians. Key allegations include:

• Failure to warn: Pfizer failed to include adequate warnings about the risk of meningioma in the drug’s labeling, prescribing information, and patient medication guides
• Fraudulent concealment: Pfizer knew about the meningioma risk from internal data, published studies, and regulatory actions in other countries but failed to disclose this information
• Negligence: Pfizer failed to exercise reasonable care in the design, testing, marketing, and post-market surveillance of Depo-Provera
• Strict product liability: Depo-Provera was unreasonably dangerous due to its defective labeling and failure to warn of known risks

MDL Consolidation Efforts

As of early 2025, motions have been filed with the Judicial Panel on Multidistrict Litigation (JPML) seeking to consolidate all federal Depo-Provera meningioma cases into a single MDL proceeding. MDL consolidation would streamline pretrial proceedings, prevent conflicting rulings, and coordinate discovery across all cases. Whether and where the JPML will create an MDL is still pending as of this writing.

International Regulatory Actions

International regulatory responses have been more aggressive than the FDA’s:

• France: The French National Agency for the Safety of Medicines and Health Products (ANSM) restricted the use of several progestogen-based drugs after studies linked them to meningioma. While Depo-Provera specifically was not banned, the French regulatory response has been cited in U.S. litigation as evidence that the pharmaceutical industry was aware of the risk.
• European Medicines Agency (EMA): The EMA has conducted reviews of progestogen products in relation to meningioma risk and has required updated warnings on certain products.

Eligibility: Who Can File a Depo-Provera Meningioma Claim?

Basic Eligibility Criteria

1. Depo-Provera use: You must have received Depo-Provera (medroxyprogesterone acetate) injections. The strength of the claim generally increases with the duration of use. Women who received injections for one year or more typically have stronger claims, with the strongest claims involving use for three or more years.
2. Meningioma diagnosis: You must have been diagnosed with a meningioma (any WHO grade) through imaging (MRI or CT scan) and/or surgical pathology.
3. Temporal relationship: The meningioma diagnosis must have occurred during or after a period of Depo-Provera use, with a biologically plausible time frame between exposure and tumor development.

Documentation Needed

• Medical records: Records documenting your Depo-Provera prescriptions and injections, including dates, dosages, and administering providers
• Pharmacy records: Prescription fill records from pharmacies
• Diagnostic records: MRI/CT scan reports, surgical reports, and pathology reports documenting your meningioma diagnosis
• Treatment records: Records of any surgery, radiation, or other treatment for your meningioma
• Insurance records: Claims data showing Depo-Provera injections and meningioma treatment

Symptoms of Meningioma to Watch For

If you have used Depo-Provera for an extended period, be aware of symptoms that may indicate a meningioma:

• Persistent or worsening headaches, particularly morning headaches
• Vision changes, including blurred or double vision
• Hearing loss or ringing in the ears (tinnitus)
• Memory problems or cognitive decline
• Seizures
• Weakness in the arms or legs
• Speech difficulties
• Personality or behavioral changes
• Loss of smell

If you are experiencing any of these symptoms and have a history of Depo-Provera use, we strongly encourage you to discuss the possibility of a meningioma with your healthcare provider and request appropriate imaging studies (MRI with contrast).

Georgia-Specific Legal Considerations

Georgia Statute of Limitations for Pharmaceutical Claims

Georgia’s personal injury statute of limitations is two years from the date of injury under O.C.G.A. § 9-3-33. For pharmaceutical product liability claims, the statute generally begins to run when the plaintiff discovers or reasonably should have discovered the connection between the drug and the injury.

In Depo-Provera meningioma cases, the “discovery” date is a critical and potentially complex determination. Many women were diagnosed with meningiomas years ago but did not learn until recently that their tumor may have been caused by Depo-Provera. The publication of the 2024 BMJ study and the subsequent media coverage and litigation may serve as a triggering event for the discovery rule in some cases. However, this is a fact-specific analysis that requires careful legal evaluation.

Georgia Product Liability Law

Under O.C.G.A. § 51-1-11, Georgia recognizes strict liability claims for products that are defective and unreasonably dangerous. For pharmaceutical products, the primary theory of liability is typically failure to warn — the manufacturer failed to provide adequate warnings about known or reasonably foreseeable risks to patients and prescribing physicians.

Georgia also recognizes the learned intermediary doctrine, which holds that a pharmaceutical manufacturer’s duty to warn runs primarily to the prescribing physician rather than directly to the patient. Under this doctrine, the manufacturer must provide adequate warnings to the physician, who then exercises professional judgment in deciding whether to prescribe the medication. However, if the manufacturer’s warnings are inadequate or misleading, the learned intermediary doctrine does not protect the manufacturer.

Georgia’s Statute of Repose

Georgia’s 10-year statute of repose under O.C.G.A. § 51-1-11(b)(2) generally bars product liability claims brought more than 10 years after the first sale of the product. However, for pharmaceutical products that are administered over a period of years, the repose period may be calculated from the date of the last injection rather than the first. This is another area requiring case-specific legal analysis.

Georgia Damages

If your Depo-Provera meningioma claim is successful, Georgia law allows you to recover:

• Economic damages: Medical expenses (past and future), lost wages, diminished earning capacity, and out-of-pocket costs
• Non-economic damages: Pain and suffering, emotional distress, mental anguish, and loss of enjoyment of life
• Punitive damages: Under O.C.G.A. § 51-12-5.1, punitive damages may be available if Pfizer is found to have acted with willful misconduct, fraud, or wanton disregard for the rights of others. Georgia caps punitive damages at $250,000 unless the defendant acted with specific intent to harm or was under the influence of drugs or alcohol. However, if the case is filed under federal law or in another state’s MDL, different caps may apply.
• Loss of consortium: Your spouse may have a separate claim for loss of companionship and marital relationship

What Pfizer Knew and When

A central issue in the Depo-Provera litigation is what Pfizer knew about the meningioma risk and whether it fulfilled its legal duty to warn. Key facts in the litigation include:

• Progesterone receptor science has been established for decades. The fact that meningiomas express progesterone receptors has been known since the 1980s. Any pharmaceutical company selling a progestogen product had a duty to monitor the scientific literature and evaluate whether their product could stimulate meningioma growth.
• International regulatory warnings preceded U.S. action. French and European authorities took regulatory action regarding progestogens and meningiomas before similar steps were taken in the United States, suggesting that the risk was known in the pharmaceutical industry.
• The Depo-Provera label lacked meningioma warnings. For years, the Depo-Provera prescribing information did not include an adequate warning about meningioma risk. Even as scientific evidence accumulated, Pfizer did not update the labeling to clearly inform physicians and patients of the meningioma association.
• Post-market surveillance should have identified the signal. Pharmaceutical manufacturers are required by FDA regulations to monitor adverse event reports and conduct post-market surveillance. Plaintiffs allege that Pfizer received adverse event reports of meningiomas in Depo-Provera users and failed to act on this safety signal.

Treatment and Impact of Meningiomas

Understanding the severity of meningiomas is important for appreciating the damages in these cases. Treatment and outcomes depend on the tumor’s size, location, and grade:

Treatment Options

• Surgical resection (craniotomy): The primary treatment for symptomatic meningiomas. Brain surgery carries inherent risks including infection, bleeding, stroke, neurological deficits, and in rare cases, death.
• Radiation therapy: Used when surgical removal is incomplete, the tumor is inoperable due to location, or the tumor recurs. Options include conventional radiation, stereotactic radiosurgery (Gamma Knife), and proton beam therapy.
• Observation (“watchful waiting”): For small, asymptomatic meningiomas, serial MRI monitoring may be appropriate. However, the psychological burden of knowing you have a brain tumor and the need for ongoing surveillance are themselves significant.

Long-Term Impact

Even when meningiomas are successfully treated, patients often experience lasting effects:

• Cognitive impairment (memory, concentration, executive function)
• Chronic headaches
• Seizure disorders requiring long-term medication
• Vision or hearing deficits
• Personality and mood changes
• Fatigue
• Anxiety and depression related to the diagnosis and the risk of recurrence
• Meningioma recurrence (grade 2 and 3 tumors have significant recurrence rates)

The Filing Process: How Depo-Provera Claims Work

Understanding how the litigation process works can help you make informed decisions about pursuing a claim:

Step 1: Free Case Evaluation

Our attorneys begin with a comprehensive evaluation of your case. We review your Depo-Provera injection history (dates, duration, and prescribing physician), your meningioma diagnosis and treatment records, your medical history to assess alternative risk factors, and your current symptoms and prognosis. This initial consultation is completely free and confidential. We will provide an honest assessment of whether you have a viable claim.

Step 2: Filing Your Claim

If your case meets the eligibility criteria, we prepare and file your individual complaint. If an MDL has been established, your case will be transferred to the MDL court for coordinated pretrial proceedings. If the cases remain in individual courts, we file in the most appropriate jurisdiction.

Step 3: Discovery and Expert Development

The discovery phase involves extensive evidence gathering from Pfizer, including internal documents about what the company knew regarding meningioma risk, communications with the FDA, marketing materials, adverse event reports, and clinical data. Our attorneys also work with medical and scientific experts to develop causation opinions linking your Depo-Provera use to your meningioma.

Step 4: Resolution

Pharmaceutical mass tort cases are typically resolved through a combination of bellwether trials (representative cases tried first to establish valuation), individual settlements, or global settlement programs. The process can take several years, but our attorneys keep you informed at every stage. Throughout the litigation, you should continue to follow your physicians’ treatment recommendations and focus on your health.

Preserving Your Medical Records

One important step you can take now is to begin gathering and preserving relevant medical records. Key documents include records from any provider who administered your Depo-Provera injections, pharmacy records showing Depo-Provera prescription fills, MRI and CT scan reports showing your meningioma, surgical and pathology reports if you had surgery, and any communications from your doctor discussing the relationship between hormonal contraceptives and your condition. Our attorneys can assist with records collection, but having these documents organized accelerates the process.

Frequently Asked Questions About Depo-Provera Meningioma Claims

I received Depo-Provera injections years ago. Can I still file a lawsuit?

Potentially, yes. The statute of limitations for pharmaceutical product liability claims depends on when you were diagnosed with a meningioma and when you became aware (or should have become aware) that your meningioma may be connected to Depo-Provera use. Given that the scientific evidence has only recently become widely known, many women may still be within the filing window. Contact our office immediately for a case-specific evaluation.

I was diagnosed with a meningioma but my doctor said it was benign. Do I still have a case?

Yes. Even “benign” (WHO Grade 1) meningiomas can cause serious symptoms, require brain surgery or radiation, and significantly impact your quality of life. The term “benign” in the context of brain tumors is misleading — it refers to the tumor’s cellular characteristics, not its clinical impact. If your meningioma required treatment or caused symptoms, you may have a viable claim.

I only used Depo-Provera for a short time. Do I qualify?

The strength of a Depo-Provera meningioma claim generally increases with the duration of use. Women who used Depo-Provera for one year or more typically have the strongest claims. However, the biological mechanism (progesterone receptor stimulation) could potentially operate even with shorter exposures. Contact our office so we can evaluate your specific use history and diagnosis.

How much is a Depo-Provera meningioma case worth?

It is too early in the litigation to predict specific case values. Compensation depends on numerous factors including the severity of your meningioma (size, grade, location), the treatment required (surgery, radiation, ongoing monitoring), the impact on your daily life, cognitive and neurological effects, lost wages, and other damages. We do not make promises about specific dollar amounts, but we will provide honest assessments based on the facts of your case.

Does using other hormonal birth control affect my claim?

If you used other hormonal contraceptives (birth control pills, hormonal IUDs, implants) in addition to Depo-Provera, this may be relevant to your case but does not necessarily disqualify your claim. The key issue is whether Depo-Provera was a substantial contributing factor in the development of your meningioma. Our attorneys work with medical experts to evaluate causation in cases involving multiple hormone exposures.

What if I am currently using Depo-Provera?

If you are currently using Depo-Provera and are concerned about meningioma risk, we strongly recommend discussing your concerns with your prescribing physician. Do not stop any medication without medical guidance. If you have symptoms suggestive of a meningioma (persistent headaches, vision changes, seizures, cognitive changes), request an evaluation from your doctor, including MRI imaging if appropriate.

How long will the Depo-Provera litigation take?

Mass tort pharmaceutical litigation typically takes several years from the initial filing to resolution. The Depo-Provera meningioma litigation is in its relatively early stages. If an MDL is established, the process will include coordinated discovery, bellwether trials, and potential settlement negotiations. We keep all clients informed of developments throughout the process.

Is there a class action lawsuit for Depo-Provera?

The Depo-Provera litigation is not a class action. It is an MDL (multidistrict litigation), which is a fundamentally different legal structure. In an MDL, each plaintiff has their own individual case with their own specific facts, injuries, and damages. Cases are consolidated only for pretrial efficiency (discovery, motions). Each case is evaluated and potentially resolved individually. This is important because it means your compensation will be based on your specific injuries, not a one-size-fits-all class settlement.

Related Practice Areas

• Mass Tort Litigation
• Brain Injury Lawyer
• Wrongful Death Lawyer
• Hair Relaxer Lawsuit Lawyer